JonesResearch analyst Justin Walsh initiated coverage of Clene (CLNN) with a Buy rating and $30 price target Clene is a clinical-stage pharmaceutical company developing nanothechnology therapeutics for the treatment of central nervous system disorders, the analyst tells investors in a research note. The firm says the company’s clinical setbacks in amyotrophic lateral sclerosis “are not the end of the story.” The market has written off potential accelerated approval prematurely, contends JonesResearch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Promising Potential of Clene’s CNM-Au8 in MS: Analyst Recommends Buy Rating
- Clene Showcases CNM-Au8® Advancements at Neurology Session
- Clene announces evidence of remyelination, neuronal repair with CNM-Au8
- Clene’s Strategic Advancements and Financial Position Reinforce Buy Rating for CNM-Au8’s Promising Future
- Clene files $160M mixed securities shelf